Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer

Amir H. Khandani, Kathleen D. Whitney, Steven M. Keller, Carmen R. Isasi, M. Donald Blaufox

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

OBJECTIVE: To estimate the sensitivity of [F] fluorodeoxyglucose (FDG) positron emission tomography (PET) and to assess the expression of glucose transporter 1 (GLUT1) and proliferative index (PI) in bronchioloalveolar lung cancer (BAC). METHODS: Twenty-four patients with resected BAC underwent preoperative PET between October 1996 and February 2003. The surgical specimens were re-examined, and 18 patients who fulfilled the 1999 WHO definition for BAC were included in the study. The PET images were reviewed in order to determine the positive (PET+) and negative (PET-) tumours on PET. The pathology slides were stained with antibodies to GLUT1 and Proliferating cell nuclear antigen (PCNA) in order to determine GLUT1 expression and PI, respectively. RESULTS: There were 13 cases of PET+ BAC (sensitivity, 72%; confidence interval, 52-93%); seven of them were GLUT1+ cases and six were GLUT1-. The stromal cell PI was significantly higher in GLUT1+ BAC compared to GLUT- BAC (50.9±17.1 vs. 33.2±14.2, P=0.0286), and higher in PET+ BAC compared to PET- BAC (45.5±15.3 vs. 29.6±19.6, P=0.0854). CONCLUSION: After applying the 1999 WHO criteria, the sensitivity of PET for detecting BAC is still relatively low. Other glucose transporters such as GLUT3 likely play a role in FDG uptake in BAC. GLUT1+ or PET+ BAC tumours have a higher stromal cell PI when compared to GLUT1- BAC or PET- BAC tumours, respectively.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalNuclear Medicine Communications
Volume28
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Facilitative Glucose Transport Proteins
Positron-Emission Tomography
Lung Neoplasms
Stromal Cells
Neoplasms
Proliferating Cell Nuclear Antigen

Keywords

  • Bronchioloalveolar lung cancer
  • FDG
  • Glucose transporter
  • PET
  • Proliferating cell nuclear antigen
  • Proliferative index

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer. / Khandani, Amir H.; Whitney, Kathleen D.; Keller, Steven M.; Isasi, Carmen R.; Donald Blaufox, M.

In: Nuclear Medicine Communications, Vol. 28, No. 3, 03.2007, p. 173-177.

Research output: Contribution to journalArticle

@article{250a82fe71e24f6da0ef2e61735db8d0,
title = "Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer",
abstract = "OBJECTIVE: To estimate the sensitivity of [F] fluorodeoxyglucose (FDG) positron emission tomography (PET) and to assess the expression of glucose transporter 1 (GLUT1) and proliferative index (PI) in bronchioloalveolar lung cancer (BAC). METHODS: Twenty-four patients with resected BAC underwent preoperative PET between October 1996 and February 2003. The surgical specimens were re-examined, and 18 patients who fulfilled the 1999 WHO definition for BAC were included in the study. The PET images were reviewed in order to determine the positive (PET+) and negative (PET-) tumours on PET. The pathology slides were stained with antibodies to GLUT1 and Proliferating cell nuclear antigen (PCNA) in order to determine GLUT1 expression and PI, respectively. RESULTS: There were 13 cases of PET+ BAC (sensitivity, 72{\%}; confidence interval, 52-93{\%}); seven of them were GLUT1+ cases and six were GLUT1-. The stromal cell PI was significantly higher in GLUT1+ BAC compared to GLUT- BAC (50.9±17.1 vs. 33.2±14.2, P=0.0286), and higher in PET+ BAC compared to PET- BAC (45.5±15.3 vs. 29.6±19.6, P=0.0854). CONCLUSION: After applying the 1999 WHO criteria, the sensitivity of PET for detecting BAC is still relatively low. Other glucose transporters such as GLUT3 likely play a role in FDG uptake in BAC. GLUT1+ or PET+ BAC tumours have a higher stromal cell PI when compared to GLUT1- BAC or PET- BAC tumours, respectively.",
keywords = "Bronchioloalveolar lung cancer, FDG, Glucose transporter, PET, Proliferating cell nuclear antigen, Proliferative index",
author = "Khandani, {Amir H.} and Whitney, {Kathleen D.} and Keller, {Steven M.} and Isasi, {Carmen R.} and {Donald Blaufox}, M.",
year = "2007",
month = "3",
doi = "10.1097/MNM.0b013e328013ebc5",
language = "English (US)",
volume = "28",
pages = "173--177",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer

AU - Khandani, Amir H.

AU - Whitney, Kathleen D.

AU - Keller, Steven M.

AU - Isasi, Carmen R.

AU - Donald Blaufox, M.

PY - 2007/3

Y1 - 2007/3

N2 - OBJECTIVE: To estimate the sensitivity of [F] fluorodeoxyglucose (FDG) positron emission tomography (PET) and to assess the expression of glucose transporter 1 (GLUT1) and proliferative index (PI) in bronchioloalveolar lung cancer (BAC). METHODS: Twenty-four patients with resected BAC underwent preoperative PET between October 1996 and February 2003. The surgical specimens were re-examined, and 18 patients who fulfilled the 1999 WHO definition for BAC were included in the study. The PET images were reviewed in order to determine the positive (PET+) and negative (PET-) tumours on PET. The pathology slides were stained with antibodies to GLUT1 and Proliferating cell nuclear antigen (PCNA) in order to determine GLUT1 expression and PI, respectively. RESULTS: There were 13 cases of PET+ BAC (sensitivity, 72%; confidence interval, 52-93%); seven of them were GLUT1+ cases and six were GLUT1-. The stromal cell PI was significantly higher in GLUT1+ BAC compared to GLUT- BAC (50.9±17.1 vs. 33.2±14.2, P=0.0286), and higher in PET+ BAC compared to PET- BAC (45.5±15.3 vs. 29.6±19.6, P=0.0854). CONCLUSION: After applying the 1999 WHO criteria, the sensitivity of PET for detecting BAC is still relatively low. Other glucose transporters such as GLUT3 likely play a role in FDG uptake in BAC. GLUT1+ or PET+ BAC tumours have a higher stromal cell PI when compared to GLUT1- BAC or PET- BAC tumours, respectively.

AB - OBJECTIVE: To estimate the sensitivity of [F] fluorodeoxyglucose (FDG) positron emission tomography (PET) and to assess the expression of glucose transporter 1 (GLUT1) and proliferative index (PI) in bronchioloalveolar lung cancer (BAC). METHODS: Twenty-four patients with resected BAC underwent preoperative PET between October 1996 and February 2003. The surgical specimens were re-examined, and 18 patients who fulfilled the 1999 WHO definition for BAC were included in the study. The PET images were reviewed in order to determine the positive (PET+) and negative (PET-) tumours on PET. The pathology slides were stained with antibodies to GLUT1 and Proliferating cell nuclear antigen (PCNA) in order to determine GLUT1 expression and PI, respectively. RESULTS: There were 13 cases of PET+ BAC (sensitivity, 72%; confidence interval, 52-93%); seven of them were GLUT1+ cases and six were GLUT1-. The stromal cell PI was significantly higher in GLUT1+ BAC compared to GLUT- BAC (50.9±17.1 vs. 33.2±14.2, P=0.0286), and higher in PET+ BAC compared to PET- BAC (45.5±15.3 vs. 29.6±19.6, P=0.0854). CONCLUSION: After applying the 1999 WHO criteria, the sensitivity of PET for detecting BAC is still relatively low. Other glucose transporters such as GLUT3 likely play a role in FDG uptake in BAC. GLUT1+ or PET+ BAC tumours have a higher stromal cell PI when compared to GLUT1- BAC or PET- BAC tumours, respectively.

KW - Bronchioloalveolar lung cancer

KW - FDG

KW - Glucose transporter

KW - PET

KW - Proliferating cell nuclear antigen

KW - Proliferative index

UR - http://www.scopus.com/inward/record.url?scp=33846703626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846703626&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e328013ebc5

DO - 10.1097/MNM.0b013e328013ebc5

M3 - Article

C2 - 17264775

AN - SCOPUS:33846703626

VL - 28

SP - 173

EP - 177

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 3

ER -